Blank, M., 		Mandel, M., 		Dror, N., 		Solomon, A., 		Barlyia, T., & 		Lavie, D.
(2017).
 Hypericin targets multiple signaling mediators in cancer cells generating unique, diverse anti-tumoral, anti-metastatic, and anti-angiogenic activities with evidence for clinical applicability.
<em>Medical Research Archives, 5</em>(3).
Retrieved from <a href="https://esmed.org/MRA/mra/article/view/881" target="_new">https://esmed.org/MRA/mra/article/view/881</a>